Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Darretta appreciation day

Executive Summary

Johnson & Johnson's outgoing CFO Robert Darretta is showered with accolades and well wishes from analysts during the company's third quarter earnings call Oct. 17. Effective Jan. 1, J&J VP-Group Finance Dominic Caruso will replace the retiring Darretta (1"The Pink Sheet" Oct. 16, 2006, In Brief). In response to the overwhelming support, Darretta said "well, gee, if I had known there was that much love and support I may have changed my decision!" However, he notes that "by the time I retire next year it's going to be nearly 39 years at J&J, a very full career and time to move onto something else, and give the exceptional talent that we have here at Johnson & Johnson [an opportunity] to contribute in even more important ways." J&J is also facing the loss of Company Group Chairman William McComb, who is taking over as CEO of Liz Claiborne...

You may also be interested in...

J&J appoints new CFO

Johnson & Johnson VP-Group Finance Dominic Caruso will replace Chief Financial Officer Robert Darretta following Darretta's retirement early next year. Effective Jan. 1, Caruso will take over as CFO and Corporate VP-Finance. Caruso, who has led J&J's finance group for less than a year, joined the company in 1999 through the acquisition of Centocor, where he was VP-finance. He has also held several positions in the device group...

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts